Shares of Hologic, Inc. (NASDAQ:HOLX – Get Free Report) have received a consensus recommendation of “Hold” from the nine research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $87.00.
HOLX has been the subject of several recent research reports. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. William Blair reiterated an “outperform” rating on shares of Hologic in a report on Friday, February 2nd. Evercore ISI boosted their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a report on Thursday, April 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a research note on Wednesday, April 10th. Finally, Raymond James boosted their target price on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd.
View Our Latest Stock Analysis on HOLX
Insider Buying and Selling at Hologic
Institutional Investors Weigh In On Hologic
Hedge funds and other institutional investors have recently modified their holdings of the stock. Nordea Investment Management AB boosted its holdings in Hologic by 4.5% in the third quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after purchasing an additional 69,494 shares during the period. Pathstone Family Office LLC grew its holdings in shares of Hologic by 96.0% during the third quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock valued at $643,000 after purchasing an additional 4,542 shares during the last quarter. Ontario Teachers Pension Plan Board raised its position in shares of Hologic by 186.7% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock worth $2,665,000 after purchasing an additional 25,010 shares during the period. HB Wealth Management LLC boosted its position in Hologic by 18.1% during the 3rd quarter. HB Wealth Management LLC now owns 5,774 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 884 shares during the period. Finally, McGuire Investment Group LLC grew its position in shares of Hologic by 0.3% during the fourth quarter. McGuire Investment Group LLC now owns 139,161 shares of the medical equipment provider’s stock worth $9,943,000 after acquiring an additional 366 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.
Hologic Stock Up 0.2 %
Shares of NASDAQ HOLX opened at $75.10 on Tuesday. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The stock has a market cap of $17.63 billion, a P/E ratio of 35.59, a PEG ratio of 2.54 and a beta of 1.00. The business’s fifty day simple moving average is $75.71 and its 200-day simple moving average is $72.50. Hologic has a 12-month low of $64.02 and a 12-month high of $87.88.
Hologic (NASDAQ:HOLX – Get Free Report) last released its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.03. The business had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.07 EPS. As a group, equities analysts predict that Hologic will post 4.02 EPS for the current fiscal year.
About Hologic
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Read More
- Five stocks we like better than Hologic
- ETF Screener: Uses and Step-by-Step Guide
- Comprehensive PepsiCo Stock Analysis
- What Does a Stock Split Mean?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.